Despite this considerable attention, hospital-acquired MRSA infections remain a major cause of preventable hospital mortality in the US [2]. Roughly 20% of healthy individuals are consistently Temozolomide colonized with Staphylococcus aureus, while another 30% are intermittently colonized [5]. Although many MRSA carriers remain asymptomatic, carriage does increase the risk of MRSA infection and can be transmitted to other individuals [5]. There is controversy over the proper role of MRSA decolonization in the prevention of MRSA infections, though some advocate for a policy

of decolonization [6]. Support for institutionalizing the practice of decolonization is based on the presumption that MRSA eradication can lower the risk of subsequent MRSA infection and may decrease transmission to other individuals. MRSA decolonization with the topical agent, mupirocin, has not been widely practiced for several reasons, including concern that widespread use could lead to resistance [7, 8], uncertainty surrounding mupirocin’s decolonizing efficacy [9], and the absence of an endorsement of this strategy in national guidelines. Since October 2007, universal nasal surveillance with contact isolation for patients who screen positive for MRSA has been standard procedure across Department of Veterans Affairs (VA) hospitals [10]. Some facilities also choose to decolonize

patients, although it is not required or encouraged as part of VA see more policy. The purpose of the present study was to assess the

impact of decolonization on subsequent Cediranib (AZD2171) MRSA carriage in a cohort of patients admitted to any of 111 VA hospitals across the US. The authors hypothesized that use of mupirocin would be associated with a reduced probability of subsequent MRSA carriage. Materials and Methods This study was approved by the University of Utah Institutional Review Board and the VA Salt Lake City Office of Research. Subjects Patients included in this study were those with an inpatient admission to a VA hospital between January 1, 2008 and December 31, 2009 who had a positive MRSA screen on admission and a subsequent Niraparib re-admission during the same time period. Exposure and Outcome Variables The exposure of interest in this study was treatment with mupirocin, a topical agent applied nasally, for MRSA decolonization. Patients were classified as having been exposed to decolonization if mupirocin was ordered or dispensed for the patient during their initial inpatient stay. The outcome in this study was subsequent MRSA carriage, as measured by surveillance swabs collected from the nares. The authors measured this at four time periods (<30, 30–60, 60–120, and >120 days), using each patient’s MRSA screening test result at the time of first re-admission.